Skip to content
DraconiticResearch
Search Sources API
210,089 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BY 4.0ACS Chemical Neuroscience

Next-Generation Psychedelic Drug Development

  • Lindsay P. Cameron1
  • Matthew W. Johnson2
  • Kevin S. Murnane3,4,5
  • Mark M. Rasenick6,7,8
  • Charles D. Nichols9
9 affiliations
  1. 1Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California 94305, United States
  2. 2Center of Excellence for Psilocybin Research and Treatment, Sheppard Pratt, Baltimore, Maryland 21204, United States
  3. 3Department of Pharmacology, Toxicology & Neuroscience, School of Graduate Studies, Louisiana State University Health Shreveport, Shreveport, Louisiana 71103, United States
  4. 4Louisiana Addiction Research Center, Louisiana State University Health Shreveport, Shreveport, Louisiana 71103, United States
  5. 5Department of Psychiatry and Behavioral Medicine, School of Medicine, Louisiana State University Health Shreveport, Shreveport, Louisiana 71103, United States
  6. 6Departments of Physiology & Biophysics and Psychiatry, University of Illinois College of Medicine, Chicago, Illinois 60612, United States
  7. 7Jesse Brown VA Medical Center, Chicago, Illinois 60612, United States
  8. 8Pax Neuroscience, Glenview, Illinois 60015, United States
  9. 9Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, United States
Read full textDOICite

Abstract

Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.

Related

  1. CCKBR (Gastrin Receptor) as a Theranostic Target in Oncology: Biological Rationale, Diagnostic Imaging, and Next-Generation Peptide-Based Drug Development.
    Ming-Cheng Chang, Chun-Tang Chen, Wan-Chi Lee +2
    PharmaceuticsPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC
  2. Advancing the Translational Pipeline: From In Vivo and In Vitro 2D Models to Next-Generation Cell Culture Models for Amyotrophic Lateral Sclerosis Modelling and Drug Discovery
    Elisabetta Carata, Stefania Mariano, Bernardetta Anna Tenuzzo +1
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Exploiting key metabolic pathways of Mycobacterium tuberculosis for next-generation anti-tubercular drug discovery.
    N Thansila Parvin, Kaushik Chanda, M M Balamurali
    Biochemistry and biophysics reportsPeer-reviewedCC BYFull textInfectious diseaseEurope PMC
  4. Effects of psychedelic drug use on neurocognitive function and the psychological and social domains of quality of life: an international online study.
    Franziska Stadler, Johan Saelens, Ioline D Henter +6
    Frontiers in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  5. Development and Psychometric Validation of the ‘Psychedelic Flourishing Scale’
    Frederick Pattisson, Sunjeev Kamboj, Devon Stoliker +1
    PsyArXivPreprintCC BY 4.0Full textPsychiatry & mental healthOSF

Cite

BibTeXRIS
BibTeX
@article{cameron2026nextgeneration,
  title = {{Next-Generation Psychedelic Drug Development}},
  author = {Lindsay P. Cameron and Matthew W. Johnson and Kevin S. Murnane and Mark M. Rasenick and Charles D. Nichols},
  journal = {ACS Chemical Neuroscience},
  year = {2026},
  month = sep,
  doi = {10.1021/acschemneuro.6c00492},
  url = {https://doi.org/10.1021/acschemneuro.6c00492},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Next-Generation Psychedelic Drug Development
AU  - Lindsay P. Cameron
AU  - Matthew W. Johnson
AU  - Kevin S. Murnane
AU  - Mark M. Rasenick
AU  - Charles D. Nichols
PY  - 2026
DA  - 2026/09/14
JO  - ACS Chemical Neuroscience
DO  - 10.1021/acschemneuro.6c00492
UR  - https://doi.org/10.1021/acschemneuro.6c00492
AB  - Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.
SN  - 1948-7193
ER  -